DK0680326T3 - Farmaceutisk formulering af nikotinafhængighed. - Google Patents

Farmaceutisk formulering af nikotinafhængighed.

Info

Publication number
DK0680326T3
DK0680326T3 DK94905025.6T DK94905025T DK0680326T3 DK 0680326 T3 DK0680326 T3 DK 0680326T3 DK 94905025 T DK94905025 T DK 94905025T DK 0680326 T3 DK0680326 T3 DK 0680326T3
Authority
DK
Denmark
Prior art keywords
pct
pharmaceutical formulation
nicotine addiction
sec
date
Prior art date
Application number
DK94905025.6T
Other languages
English (en)
Inventor
Joachim Arnold Moormann
Original Assignee
Hf Arzneimittelforsch Gmbh
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hf Arzneimittelforsch Gmbh, Lohmann Therapie Syst Lts filed Critical Hf Arzneimittelforsch Gmbh
Application granted granted Critical
Publication of DK0680326T3 publication Critical patent/DK0680326T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
DK94905025.6T 1993-01-23 1994-01-10 Farmaceutisk formulering af nikotinafhængighed. DK0680326T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4301782A DE4301782C1 (de) 1993-01-23 1993-01-23 Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit

Publications (1)

Publication Number Publication Date
DK0680326T3 true DK0680326T3 (da) 1997-06-23

Family

ID=6478780

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94905025.6T DK0680326T3 (da) 1993-01-23 1994-01-10 Farmaceutisk formulering af nikotinafhængighed.

Country Status (23)

Country Link
US (1) US5643905A (da)
EP (1) EP0680326B1 (da)
JP (1) JP3511074B2 (da)
KR (1) KR100301547B1 (da)
AT (1) ATE146677T1 (da)
AU (1) AU685075B2 (da)
CZ (1) CZ284605B6 (da)
DE (2) DE4301782C1 (da)
DK (1) DK0680326T3 (da)
ES (1) ES2098920T3 (da)
GR (1) GR3022862T3 (da)
HR (1) HRP940029B1 (da)
HU (1) HU221159B1 (da)
IL (1) IL108234A (da)
MY (1) MY111260A (da)
NO (1) NO306894B1 (da)
NZ (1) NZ259858A (da)
PL (1) PL174812B1 (da)
SI (1) SI9400028A (da)
SK (1) SK282247B6 (da)
WO (1) WO1994016708A1 (da)
YU (1) YU48559B (da)
ZA (1) ZA94413B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
AT402691B (de) * 1996-01-26 1997-07-25 Sanochemia Ltd Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU1738800A (en) * 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
PL349501A1 (en) * 1998-12-24 2002-07-29 Janssen Pharmaceutica Nv Controlled release galantamine composition
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
WO2001043697A2 (en) * 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
DE10018834A1 (de) * 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
DE10119862A1 (de) 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
BG65658B1 (bg) * 2003-11-13 2009-05-29 "Софарма" Ад Комбиниран лекарствен продукт на основата на галантамин
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20050277626A1 (en) * 2004-05-27 2005-12-15 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
BR112012024356A2 (pt) 2010-03-26 2016-05-24 Philip Morris Products Sa inibição de irritação sensorial durante o consumo de tabaco não fumável
CN101829068A (zh) * 2010-05-06 2010-09-15 徐州市光合生物营养品有限公司 一种水溶性药物缓释片及其制备方法
BG66818B1 (bg) 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
US10335378B2 (en) 2013-03-15 2019-07-02 Altria Client Services Llc Inhibition of central nervous system effects from smoking and sensory effects from smoking
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3760805A (en) * 1971-01-13 1973-09-25 Alza Corp Osmotic dispenser with collapsible supply container
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
DE3843239C1 (da) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK0584185T3 (da) * 1991-05-14 2000-02-07 Ernir Snorrason Behandling af træthedssyndrom med cholinesteraseinhibitorer

Also Published As

Publication number Publication date
JPH08505633A (ja) 1996-06-18
SI9400028A (en) 1994-09-30
IL108234A (en) 1996-10-31
CZ284605B6 (cs) 1999-01-13
AU685075B2 (en) 1998-01-15
YU2494A (sh) 1997-01-08
NZ259858A (en) 1997-03-24
HRP940029B1 (en) 2000-06-30
ATE146677T1 (de) 1997-01-15
NO952906D0 (no) 1995-07-21
ZA94413B (en) 1994-09-09
KR100301547B1 (ko) 2001-10-22
DE4301782C1 (de) 1994-08-25
PL174812B1 (pl) 1998-09-30
SK282247B6 (sk) 2001-12-03
HU221159B1 (en) 2002-08-28
DE59401401D1 (de) 1997-02-06
GR3022862T3 (en) 1997-06-30
KR960700061A (ko) 1996-01-19
HUT72670A (en) 1996-05-28
US5643905A (en) 1997-07-01
ES2098920T3 (es) 1997-05-01
CZ184395A3 (en) 1996-02-14
MY111260A (en) 1999-10-30
AU5881894A (en) 1994-08-15
HU9501964D0 (en) 1995-09-28
NO306894B1 (no) 2000-01-10
NO952906L (no) 1995-07-21
IL108234A0 (en) 1994-04-12
WO1994016708A1 (de) 1994-08-04
EP0680326B1 (de) 1996-12-27
EP0680326A1 (de) 1995-11-08
YU48559B (sh) 1998-11-05
HRP940029A2 (en) 1997-06-30
SK89095A3 (en) 1996-05-08
PL309604A1 (en) 1995-10-30
JP3511074B2 (ja) 2004-03-29

Similar Documents

Publication Publication Date Title
DK0680326T3 (da) Farmaceutisk formulering af nikotinafhængighed.
CZ176595A3 (en) The application of anticonvulsive agents for the preparation of medicaments intended for treating parkinson's disease and parkinson's syndromes
ATE195249T1 (de) Pharmazeutische aerosol welche mindestens ein zucker enthält
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
MY124465A (en) Reduction of infarct volume using citicoline
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
WO2000048445A3 (de) Pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DK0866711T3 (da) Anvendelse af 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamid til fremstilling af et farmaceutisk præparat til modvirkning af sövnapnö
GEP20043377B (en) Pharmaceutical Complex
DE50000864D1 (de) Verwendung von desoxypeganin zur behandlung von drogenabhängigkeit
MY122477A (en) Sertraline oral concentrate
DE59910944D1 (de) Transdermales therapeutisches system zur anwendung von candesartan
DE50010973D1 (de) Pharmazeutische zusammensetzung, enthaltend desoxypeganin zur behandlung des alkoholismus
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
DK0863752T3 (da) Anvendelse af alkylaminderivater såsom terbinafin ved fremstillingen af et lægemiddel til behandling af ledsagende sygdomme af en helicobacter pylori-infektion.
PE20011042A1 (es) Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan
ZA200100289B (en) Use of tiludronic acid and derivatives thereof in poultry for the preparation of a medicinal product for preventing and treating osteoporosis.